I-Mab
Market Cap
$237.29M
P/E Ratio
-5.69
EPS
$-0.51
Dividend Yield
0.00%
52-Week Range
$0.59 — $6.79
Volume
2.21M
Avg Volume
1.85M
Beta
1.46
P/E (TTM)
-5.69
Forward P/E
—
PEG Ratio
1.14
P/S (TTM)
0.00
P/B (TTM)
1.32
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.11%
ROA (TTM)
-0.03%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.01
Current Ratio
14.47
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
—
EPS Growth (5Y)
—
Sales Growth (3Y)
—
Sales Growth (5Y)
—
EPS Est (This Year)
$-3.62
EPS Est (Next Year)
$-2.91
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$16.10
Price Target Range
Consensus Target: $7.67(164.5% upside)
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2020-01-17
Employees
32
CEO
Xi-Yong Fu
Index Membership
—
Website
https://www.i-mabbiopharma.com
I-Mab (IMAB) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $237.29M, a P/E ratio of -5.69, IMAB is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare IMAB against other stocks using dozens of fundamental and technical filters.
CYBN
Cybin Inc.
$8.28
+1.22%
$413.02M
FRX.TO
Fennec Pharmaceuticals Inc.
$10.72
-0.05%
$295.33M
BTX
BlackRock Technology and Private Equity Term Trust
$6.49
+1.56%
$757.45M
BHVN
Biohaven Ltd.
$9.53
-1.14%
$1.01B
ABUS
Arbutus Biopharma Corporation
$4.36
+0.00%
$838.53M
LXEO
Lexeo Therapeutics, Inc. Common Stock
$6.38
-2.89%
$465.66M
I-Mab (IMAB) has a trailing twelve-month (TTM) P/E ratio of -5.69. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, I-Mab (IMAB) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
I-Mab (IMAB) has a market capitalization of $237.29 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.